Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease
Authors
Keywords
Coronary artery disease, Heart failure, Stroke
Journal
INTERNATIONAL JOURNAL OF CARDIOLOGY
Volume 349, Issue -, Pages 127-133
Publisher
Elsevier BV
Online
2021-12-03
DOI
10.1016/j.ijcard.2021.11.076
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Relationships between diuretic-related hyperuricemia and cardiovascular events
- (2020) Alessandro Maloberti et al. JOURNAL OF HYPERTENSION
- Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey 2007-2016
- (2019) Michael Chen-Xu et al. Arthritis & Rheumatology
- Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy
- (2019) Sunao Kojima et al. EUROPEAN HEART JOURNAL
- Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association
- (2019) Janani Rangaswami et al. CIRCULATION
- Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study
- (2019) Tae Ryom Oh et al. Scientific Reports
- Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years
- (2019) Agostino Virdis et al. HYPERTENSION
- Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
- (2018) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China
- (2018) Peige Song et al. Scientific Reports
- Implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial and associated FDA public safety alert
- (2018) Hyon Choi et al. Arthritis & Rheumatology
- Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial
- (2018) Kenjiro Kimura et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia
- (2017) Sunao Kojima et al. Journal of Cardiology
- Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis
- (2016) Min Li et al. Scientific Reports
- Secondary Prevention Strategy of Cardiovascular Disease Using Endothelial Function Testing
- (2015) Yasushi Matsuzawa et al. CIRCULATION JOURNAL
- Prognostic Value of Flow-Mediated Vasodilation in Brachial Artery and Fingertip Artery for Cardiovascular Events: A Systematic Review and Meta-Analysis
- (2015) Y. Matsuzawa et al. Journal of the American Heart Association
- Febuxostat improves outcome in a rat model of cancer cachexia
- (2015) Masaaki Konishi et al. Journal of Cachexia Sarcopenia and Muscle
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started